MOUNTAIN VIEW, Calif., Dec. 3, 2010 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that senior management will present an overview of the company at two investment conferences during the month of December.
|
The conference presentation schedule is as follows: |
||
|
Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference |
||
|
December 8, 2010 at 12:30 p.m. PT |
||
|
Nikko Hotel, San Francisco, CA |
||
|
Presenter: Charles Bowden, MD, director of clinical development |
||
|
2010 Deutsche Bank BioFEST Conference |
||
|
December 14, 2010 at 4:05 p.m. ET |
||
|
Four Seasons Hotel, Boston, MA |
||
|
Presenter: Timothy Morris, chief financial officer |
||
A live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.
About VIVUS
VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development is QNEXA®, which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.
|
CONTACT: |
|||
|
VIVUS, Inc. |
Investor Relations: |
The Trout Group |
|
|
Timothy E. Morris |
Brian Korb |
||
|
Chief Financial Officer |
|||
|
650-934-5200 |
646-378-2923 |
||
SOURCE VIVUS, Inc.